Table 2.

Characterization of MDA-MB-231 breast cancer cells overexpressing VEGF isoforms used in this study

(A)	Clones number	VEGF165	VEGF189	NRP1
	cV	1	1	1
Clones	V189	1.5	30.5#	1
	V165	48#	1.4	1.4
(B)	Clones number	VEGF165	VEGF189	NRP1
	shCtl	1	1	1
cV clones	shNRP1–9	0.9	0.8	0.6*
	shNRP1–19	0.5	0.5	0.4*
	shCtl	1	1	1
V189 clones	shNRP1–10	0.4*	9.7*	0.6*
	shNRP1–11	0.48*	5.8*	0.57*
	shCtl	1	1	1
V165 clones	shNRP1–3	1	0.5	0.5*
	shNRP1–5	0.7	0.6	0.4*

(A) VEGF overexpressing clones. Expression of VEGFmRNA was assessed using real-time PCR V189 clones (V189–13), V165 (V165–42) clones, and cV (cV-14) clones (for VEGF189 and VEGF165 overexpressing, or control clones, respectively), were initially described in reference 10; these clones were maintained in 10% SVF condition Data obtained using real-time PCR were expressed as mean values, as compared with cV clones set to 1. (B) ShNRP1 and shCtl transfected clones. Data, obtained in 10% FBS containing medium, were expressed as mean values of 4 independent experiments performed in duplicate, as compared with corresponding shCtl clone set to 1. Statistical significance (p < 0.05):

^#VEGF overexpressing vs. cV clone;

^*shNRP1 clone vs. shCtl clone.